Today Pandora released their annual earnings. The self explanatory figures below summarise the earnings, the margins, the ROIC and the growth for the recent comparable quarters and for the previous TTM periods by product segment and by geographic segment. Revenue and earnings Margins ROIC By product segment By geographic segment Programme NOW In November Programme …
Category Archives: Uncategorized
Novo Nordisk 2018Q4
Novo Nordisk has released their annual report. Positive growth was driven primarily by Ozempic® in the US, Saxenda®, Tresiba® and Victoza®, whereas negative growth was driven by primarily Levemir® in the US. The mentioned drugs and the trailing twelve month (TTM) sales of diabetes and obesity drugs are summarised below. Name Drug Type Injection Therapy …
Is it time to short Netflix?
Streaming giant Netflix just reported annual earnings for 2018. Reuters 2019Jan18: Netflix shares fall as weak forecast dampens investor optimism Bloomberg 2018Jan18: Netflix’s International Expansion Dominates Growth The net margins at Netflix are single digit and the P/S multiple is well above 10, which means the P/E multiple is a triple digit. Does that mean …
Brexit bombshell
Brexit is being decided by the members of parliament in the House of Commons tomorrow. Westminster could decide to go ahead with the deal negotiated by prime minister Theresa May, but “no deal” as opposed to a people’s vote (or general election or extension of article 50) cannot be ruled out completely. Below the PM …
Eli Lilly & Novo Nordisk – Episode 2018Q3 – The ongoing battle for GLP1 market share
Diabetes rivals Eli Lilly and Novo Nordisk and their smaller diabetes competitors such as Sanofi, Merck, AstraZeneca and Johnson & Johnson have all released their Q3 results. Below is a summary of Novo and Lilly and their shared therapeutic area diabetes and their shared drug class GLP1. GLP1 receptor agonists come with the HbA1c advantages …
Pandora lowers full year guidance
The jewelry maker Pandora, which is still without a CEO, sent out a press release on their Q3 results today. Expected revenue growth for 2018 was revised from 4-7% to 2-4%. Bloomberg: Pandora Plans `Reset’ in Bid to Shore Up Investor Confidence Reuters: Charm-bracelet maker Pandora warns again on sales euronews: Jeweller Pandora cuts 2018 …
VF raises dividend and full year outlook, but growth is slowing down
VF released their earnings today and raised outlook for the full year. Since the previous quarter VF has announced the sale of the Reef® brand to The Rockport Group on October 4th. And on August 13th VF announced the intention to create two independent publicly traded companies; one apparel and footwear and the other jeans …
Continue reading “VF raises dividend and full year outlook, but growth is slowing down”
Johnson & Johnson Reports 2018 Third-Quarter Results
J&J released their Q3 results today: – 2018 Third-Quarter Sales of $20.3 Billion Increased 3.6% versus 2017 – 2018 Third-Quarter EPS was $1.44 – 2018 Adjusted Third-Quarter EPS of $2.05 increased 7.9%* – Strong Operational Sales and Adjusted EPS Growth* – Company Increased Sales and EPS Guidance The Q3 results spawned the following headlines. – …
Continue reading “Johnson & Johnson Reports 2018 Third-Quarter Results”
Eli Lilly and phase results 2 on their dual GIP/GLP1 receptor agonist LY3298176
Today Ely Lilly (LLY) announced the positive results on a phase 2 diabetes drug of theirs (LY3298176) via a publication in The Lancet, a presentation at the annual meeting of the European Association for the Study of Diabetes (EASD) and the press release below: Lilly’s Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction …
Continue reading “Eli Lilly and phase results 2 on their dual GIP/GLP1 receptor agonist LY3298176”
Teva and the approval of the migraine drug Ajovy®
Teva announced the FDA approval of their migraine drug Ajovy® (Fremanezumab) – a mAB CGRP inhibitor – in a press release on September 21st. I felt it would be a good time to revisit Teva and migraine drugs, since a lot of things have happened, since their largest ever acquisition of Actavis Generics from Allergan …
Continue reading “Teva and the approval of the migraine drug Ajovy®”